Citius Pharmaceuticals, Inc. (CTXR) stock
CTXRNasdaqPharmaceutical PreparationsFiscal year ends September 30
$0.52−0.01 (-1.67%)
Close on Nov 17, 2026Market cap $14.24MP/E –Yield –
Citius Pharmaceuticals operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Citius Pharmaceuticals's operating cash flow for the twelve months ending Jun 30, 2026 was -$34.87M. For fiscal 2025 it was -$26.55M. The highest annual figure on record is -$20.32K in fiscal 2012.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | -$26.55M | – |
| FY2024 | Sep 30, 2024 | -$28.20M | – |
| FY2023 | Sep 30, 2023 | -$29.06M | – |
| FY2022 | Sep 30, 2022 | -$28.36M | – |
| FY2021 | Sep 30, 2021 | -$24.25M | – |
| FY2020 | Sep 30, 2020 | -$16.93M | – |
| FY2019 | Sep 30, 2019 | -$12.44M | – |
| FY2018 | Sep 30, 2018 | -$11.32M | – |
| FY2017 | Sep 30, 2017 | -$7.97M | – |
| FY2016 | Sep 30, 2016 | -$5.90M | – |
| FY2012 | Sep 30, 2012 | -$20.32K | – |
| FY2011 | Sep 30, 2011 | -$20.78K | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | -$8.68M | – |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | -$1.30M | – |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | -$13.01M | – |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | -$11.88M | – |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | -$5.41M | – |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | -$4.54M | – |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | -$4.73M | – |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | -$5.91M | – |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | -$8.37M | – |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | -$7.79M | – |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | -$6.14M | – |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | -$6.80M | – |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | -$4.82M | – |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | -$6.33M | – |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | -$7.71M | – |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | -$9.67M | – |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | -$4.65M | – |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | -$5.59M | – |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | -$4.82M | – |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | -$4.27M | – |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | -$9.56M | – |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | -$3.36M | – |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | -$3.99M | – |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | -$4.47M | – |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | -$5.11M | – |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | -$2.91M | – |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | -$3.52M | – |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | -$3.85M | – |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | -$2.16M | – |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | -$2.50M | – |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | -$2.25M | – |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | -$4.13M | – |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | -$2.44M | – |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | -$3.43M | – |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | -$2.40M | – |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | -$824.60K | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | -$1.31M | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | -$1.77M | – |
| Q3 FY2016CQ2 2016 | Jun 30, 2016 | -$2.56M | – |
See a number that looks wrong?